These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
815 related items for PubMed ID: 25501614
21. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France. Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall JM, Cook E, Aboulker JP, Capitant C, Molina JM, Spire B. AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083 [Abstract] [Full Text] [Related]
23. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. Myers GM, Mayer KH. AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497 [Abstract] [Full Text] [Related]
24. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM, iPrEx investigators. Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965 [Abstract] [Full Text] [Related]
25. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men. McManus H, Grulich AE, Amin J, Selvey C, Vickers T, Bavinton B, Zablotska I, Vaccher S, Jin F, Holden J, Price K, Yeung B, Cabrera Quichua G, Ogilvie E, McNulty A, Smith D, Guy R. JAMA Netw Open; 2020 Dec 01; 3(12):e2030806. PubMed ID: 33355675 [Abstract] [Full Text] [Related]
26. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, Partners PrEP Study Team. Lancet Infect Dis; 2014 Nov 01; 14(11):1055-1064. PubMed ID: 25300863 [Abstract] [Full Text] [Related]
27. Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study. Torres Silva MS, Torres TS, Coutinho C, Ismério Moreira R, da Costa Leite I, Cunha M, da Costa Leite PHA, Cáceres CF, Vega-Ramírez H, Konda KA, Guanira J, Valdez Madruga J, Wagner Cardoso S, Benedetti M, Pimenta MC, Hoagland B, Grinsztejn B, Gonçalves Veloso V, ImPrEP Study Group. Lancet HIV; 2024 Oct 01; 11(10):e670-e679. PubMed ID: 39243787 [Abstract] [Full Text] [Related]
30. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis. Hugo JM, Stall RD, Rebe K, Egan JE, De Swardt G, Struthers H, McIntyre JA. AIDS Behav; 2016 Dec 01; 20(Suppl 3):357-364. PubMed ID: 27631366 [Abstract] [Full Text] [Related]
34. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice. Li J, Dufrene SL, Okulicz JF. Ann Pharmacother; 2014 Apr 01; 48(4):507-18. PubMed ID: 24473492 [Abstract] [Full Text] [Related]
35. Interest in HIV pre-exposure prophylaxis in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France). Coulaud PJ, Sagaon-Teyssier L, M'madi Mrenda B, Maradan G, Mora M, Bourrelly M, Dembélé Keita B, Keita AA, Anoma C, Babo Yoro SA, Dah TTE, Coulibaly C, Mensah E, Agbomadji S, Bernier A, Couderc C, Laurent C, Spire B, CohMSM Study Group. Trop Med Int Health; 2018 Oct 01; 23(10):1084-1091. PubMed ID: 30055043 [Abstract] [Full Text] [Related]
36. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). Wang H, Zhang Y, Mei Z, Jia Y, Leuba SI, Zhang J, Chu Z, Ding H, Jiang Y, Geng W, Shang H, Xu J. BMC Infect Dis; 2019 Aug 15; 19(1):721. PubMed ID: 31416439 [Abstract] [Full Text] [Related]
39. Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin. Ahouada C, Diabaté S, Mondor M, Hessou S, Guédou FA, Béhanzin L, Batona G, Gning NN, Zannou DM, Alary M. BMC Public Health; 2020 Aug 20; 20(1):1267. PubMed ID: 32819335 [Abstract] [Full Text] [Related]
40. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, Loze B, Leplatois A, Aslan A, Moudachirou K, Delaugerre C, Rozenbaum W, Molina JM. AIDS; 2018 Sep 24; 32(15):2161-2169. PubMed ID: 30212403 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]